NCT07159386 Advanced Fibrosis Detection for MASLD in Primary Care
| NCT ID | NCT07159386 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University of South Carolina |
| Condition | Metabolic Dysfunction-associated Steatotic Liver Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 225 participants |
| Start Date | 2026-03-16 |
| Primary Completion | 2030-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 225 participants in total. It began in 2026-03-16 with a primary completion date of 2030-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This proposal evaluates the implementation of a novel, non-interruptive, electronic health record alert for metabolic dysfunction-associated steatotic liver disease (MASLD) fibrosis risk assessment in primary care patients with MASLD using a stepped wedge, cluster randomized design. This work will generate generalizable data to dramatically enhance MASLD management in primary care.
Eligibility Criteria
Patients Inclusion Criteria: * Patients with a diagnosis code for MASLD * Type 2 diabetes mellitus will Exclusion Criteria: * All patients with cirrhosis, complications of cirrhosis (e.g. portal hypertension, hepatic encephalopathy), hepatocellular carcinoma, or previous liver transplant will be excluded. * pregnant women. Clinicians Clinicians will also be study participants, as we will be surveying them for feedback on the MASLD fibrosis risk assessment intervention. The MUSC primary care network at last count employed 122 clinicians across the 27 primary care practices. Inclusion criteria: 1\. All physicians, physician assistants, and nurse practitioners delivering primary care during the intervention phase of the study. Exclusion criteria: None
Contact & Investigator
Andrew Schreiner, MD, MSCR
PRINCIPAL INVESTIGATOR
Medical University of South Carolina
Frequently Asked Questions
Who can join the NCT07159386 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Metabolic Dysfunction-associated Steatotic Liver Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07159386 currently recruiting?
Yes, NCT07159386 is actively recruiting participants. Contact the research team at schrein@musc.edu for enrollment information.
Where is the NCT07159386 trial being conducted?
This trial is being conducted at Charleston, United States.
Who is sponsoring the NCT07159386 clinical trial?
NCT07159386 is sponsored by Medical University of South Carolina. The principal investigator is Andrew Schreiner, MD, MSCR at Medical University of South Carolina. The trial plans to enroll 225 participants.